secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001558370-23-010987
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800
-------------------------------------------------------------------------------

- Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.
- Annual base salary reduced to $280,800; annual bonus eligibility pro-rated for part-time service.
- Amended employment agreement has initial two-year term with automatic one-year renewals unless 90-day notice given.
- Monahan remains in role; prior agreement superseded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/0001558370-23-010987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023010987/acrs-20230609x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer